Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care

In this online program centered around a dynamic CCO symposium in Orlando, experts discuss recent advances in the management of essential thrombocythemia, polycythemia vera, and myelofibrosis. Watch the on-demand Webcast and download the slides from the symposium and read expert commentaries on current and emerging therapeutic strategies for patients with MPNs.
Srdan Verstovsek, MD, PhD
Program Director
Jean-Jacques Kiladjian, MD, PhD
Raajit K. Rampal, MD, PhD
Alessandro M. Vannucchi, MD
Srdan Verstovsek, MD, PhD

ClinicalThought

Outcomes are poor for patients with myelofibrosis who discontinue ruxolitinib due to loss of response or intolerance. In this commentary, I offer my thoughts on the best treatment options for these patients.

Srdan Verstovsek, MD, PhD Released: October 7, 2019

In this commentary, Raajit K. Rampal, MD, PhD, highlights key MPN studies that will be presented at the upcoming 2019 ASH annual meeting in Orlando.

Raajit K. Rampal, MD, PhD Released: December 2, 2019

Read expert answers to key questions from the audience at a recent symposium on optimal management of patients with myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD
Program Director
Jean-Jacques Kiladjian, MD, PhD Raajit K. Rampal, MD, PhD Alessandro M. Vannucchi, MD
Released: January 16, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Celgene Corporation
CTI Biopharma
Geron

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue